CompletedPhase 2NCT01894958

A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome

Studying Fragile X syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Neuren Pharmaceuticals Limited
Principal Investigator
Elizabeth M Berry-Kravis, MD
Rush University Medical Center
Intervention
NNZ-2566(drug)
Enrollment
72 enrolled
Eligibility
12-45 years · MALE
Timeline
20142015

Study locations (17)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01894958 on ClinicalTrials.gov

Other trials for Fragile X syndrome

Additional recruiting or active studies for the same condition.

See all trials for Fragile X syndrome

← Back to all trials